MedTrace Logo

Efficacy and Safety of SOM3355 in Huntington's Disease Chorea

NCT03575676 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-09-16

No results posted yet for this study

Summary

Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease

Conditions

  • Huntington's Chorea

Interventions

DRUG

SOM3355 100mg BID

Oral

DRUG

SOM3355 200mg BID

Oral

DRUG

Placebo BID

Oral

Sponsors & Collaborators

  • SOM Innovation Biotech SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-08
Primary Completion
2019-08-22
Completion
2019-08-22

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575676 on ClinicalTrials.gov